Literature DB >> 18284365

Myocarditis, pericarditis, and dilated cardiomyopathy after smallpox vaccination among civilians in the United States, January-October 2003.

Juliette Morgan1, Martha H Roper, Laurence Sperling, Richard A Schieber, James D Heffelfinger, Christine G Casey, Jacqueline W Miller, Scott Santibanez, Barbara Herwaldt, Paige Hightower, Pedro L Moro, Beth F Hibbs, Nancy H Levine, Louisa E Chapman, John Iskander, J Michael Lane, Melinda Wharton, Gina T Mootrey, David L Swerdlow.   

Abstract

Myocarditis was reported after smallpox vaccination in Europe and Australia, but no association had been reported with the US vaccine. We conducted surveillance to describe and determine the frequency of myocarditis and/or pericarditis (myo/pericarditis) among civilians vaccinated during the US smallpox vaccination program between January and October 2003. We developed surveillance case definitions for myocarditis, pericarditis, and dilated cardiomyopathy after smallpox vaccination. We identified 21 myo/pericarditis cases among 37,901 vaccinees (5.5 per 10,000); 18 (86%) were revacinees, 14 (67%) were women, and the median age was 48 years (range, 25-70 years). The median time from vaccination to onset of symptoms was 11 days (range, 2-42 days). Myo/pericarditis severity was mild, with no fatalities, although 9 patients (43%) were hospitalized. Three additional vaccinees were found to have dilated cardiomyopathy, recognized within 3 months after vaccination. We describe an association between smallpox vaccination, using the US vaccinia strain, and myo/pericarditis among civilians.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18284365     DOI: 10.1086/524747

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  21 in total

1.  Ischemic cardiac events and other adverse events following ACAM2000(®) smallpox vaccine in the Vaccine Adverse Event Reporting System.

Authors:  Michael M McNeil; Maria Cano; Elaine R Miller; Brett W Petersen; Renata J M Engler; Marthe G Bryant-Genevier
Journal:  Vaccine       Date:  2014-06-18       Impact factor: 3.641

Review 2.  Myocarditis.

Authors:  Sandeep Sagar; Peter P Liu; Leslie T Cooper
Journal:  Lancet       Date:  2011-12-18       Impact factor: 79.321

3.  Safety and immunogenicity of LC16m8, an attenuated smallpox vaccine in vaccinia-naive adults.

Authors:  Jeffrey S Kennedy; Marc Gurwith; Cornelia L Dekker; Sharon E Frey; Kathryn M Edwards; Julie Kenner; Michael Lock; Cyril Empig; Shigeru Morikawa; Masayuki Saijo; Hiroyuki Yokote; Kevin Karem; Inger Damon; Mark Perlroth; Richard N Greenberg
Journal:  J Infect Dis       Date:  2011-09-15       Impact factor: 5.226

Review 4.  Vaccinia viruses: vaccines against smallpox and vectors against infectious diseases and tumors.

Authors:  Stephen R Walsh; Raphael Dolin
Journal:  Expert Rev Vaccines       Date:  2011-08       Impact factor: 5.217

5.  The identification of HLA class II-restricted T cell epitopes to vaccinia virus membrane proteins.

Authors:  Richard B Kennedy; Gregory A Poland
Journal:  Virology       Date:  2010-10-18       Impact factor: 3.616

6.  The heterogeneity of human antibody responses to vaccinia virus revealed through use of focused protein arrays.

Authors:  Jonathan S Duke-Cohan; Kristin Wollenick; Elizabeth A Witten; Michael S Seaman; Lindsey R Baden; Raphael Dolin; Ellis L Reinherz
Journal:  Vaccine       Date:  2009-01-13       Impact factor: 3.641

7.  Phase 1 safety and immunogenicity evaluation of ADMVA, a multigenic, modified vaccinia Ankara-HIV-1 B'/C candidate vaccine.

Authors:  Sandhya Vasan; Sarah J Schlesinger; Zhiwei Chen; Arlene Hurley; Angela Lombardo; Soe Than; Phumla Adesanya; Catherine Bunce; Mark Boaz; Rosanne Boyle; Eddy Sayeed; Lorna Clark; Daniel Dugin; Mar Boente-Carrera; Claudia Schmidt; Qing Fang; Yaoxing Huang; Gerasimos J Zaharatos; David F Gardiner; Marina Caskey; Laura Seamons; Martin Ho; Len Dally; Carol Smith; Josephine Cox; Dilbinder Gill; Jill Gilmour; Michael C Keefer; Patricia Fast; David D Ho
Journal:  PLoS One       Date:  2010-01-25       Impact factor: 3.240

Review 8.  ACAM2000: the new smallpox vaccine for United States Strategic National Stockpile.

Authors:  Aysegul Nalca; Elizabeth E Zumbrun
Journal:  Drug Des Devel Ther       Date:  2010-05-25       Impact factor: 4.162

9.  Safety and immunogenicity of modified vaccinia Ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trial.

Authors:  Stephen R Walsh; Marissa B Wilck; David J Dominguez; Elise Zablowsky; Shringkhala Bajimaya; Lisa S Gagne; Kelly A Verrill; Jane A Kleinjan; Alka Patel; Ying Zhang; Heather Hill; Aruna Acharyya; David C Fisher; Joseph H Antin; Michael S Seaman; Raphael Dolin; Lindsey R Baden
Journal:  J Infect Dis       Date:  2013-03-12       Impact factor: 5.226

Review 10.  Vaccinating against monkeypox in the Democratic Republic of the Congo.

Authors:  Brett W Petersen; Joelle Kabamba; Andrea M McCollum; Robert Shongo Lushima; Emile Okitolonda Wemakoy; Jean-Jacques Muyembe Tamfum; Beatrice Nguete; Christine M Hughes; Benjamin P Monroe; Mary G Reynolds
Journal:  Antiviral Res       Date:  2018-11-14       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.